At a glance

What is GHK-Cu?

GHK-Cu is the tripeptide glycyl-L-histidyl-L-lysine bound to copper. It occurs naturally in the body and declines with age, and it is one of the most studied "copper peptides." This entry concerns the systemic, injectable wellness use for skin, hair, and tissue repair; the topical cosmetic form is cataloged separately under its ingredient name, Copper tripeptide-1. The injectable use is not an approved medicine.

How does it work?

In laboratory and animal models, GHK-Cu is described as a signal for tissue remodeling. It is reported to:

• Influence the extracellular matrix
• Deliver copper
• Act as an antioxidant and anti-inflammatory
• Support new blood-vessel formation
• Switch on gene programs¹ linked to repair

These are cell and animal findings. This describes the proposed mechanism, separate from demonstrated benefit from systemic use in people.

Is it FDA-approved?

No, not for systemic use. Injectable or systemic GHK-Cu is not an FDA-approved drug. Copper peptides sit in the contested peptide-compounding space; the FDA advisory committee reviewed several peptides in 2026, but those recommendations are non-binding and no additions to the compounding list have been finalized, so lawful compounding remains unsettled. (Topical cosmetic use is regulated separately as a cosmetic ingredient.)

What does the research show?

For systemic use, the evidence is preclinical. The table sets out what has been studied in each model, with both animal studies drawn from PubMed:

The systemic benefit is therefore an extrapolation from cell and animal work.

Frequently asked questions

What is GHK-Cu and how does it work in the body?

GHK-Cu is a naturally occurring copper-binding tripeptide consisting of glycine, histidine, and lysine complexed with a copper(II) ion, first identified in human plasma in the 1970s. Plasma concentrations decline with age⁴, falling from approximately 200 ng/mL at age 20 to around 80 ng/mL by age 60. In lab and animal studies, GHK-Cu is proposed to act as a copper complex⁵ that modulates matrix metalloproteinases (MMPs) and their inhibitors, and it affects genes involved in anti-inflammatory and antioxidant defense. Rather than operating through a single pathway, GHK-Cu appears to play a broad regulatory role across multiple biological processes.

What does the research show about GHK-Cu and collagen production?

Preclinical and early clinical research shows GHK-Cu is associated with increased collagen type I and III synthesis, starting at very low concentrations. In cultured fibroblasts, GHK-Cu stimulated collagen synthesis⁶ beginning between 10⁻¹² and 10⁻¹¹ M, with peak effect at 10⁻⁹ M, independent of cell number changes. In a rat wound-chamber study, GHK-Cu raised collagen content in a concentration-dependent way⁷ compared with saline controls, increased type I and III collagen mRNA without increasing TGF-beta mRNA, and stimulated collagen synthesis twice as much as non-collagen protein synthesis. Gene-expression data from the Broad Institute's Connectivity Map suggest GHK alters 31.2% of human genes⁴ at a ≥50% threshold, and in a thigh-skin biopsy study⁸, collagen production increased in 70% of GHK-Cu-treated women versus 50% with vitamin C cream and 40% with retinoic acid. Most collagen evidence remains in vitro, and human data are essentially limited to topical cosmetic contexts.

How does GHK-Cu affect wound healing?

GHK-Cu has a relatively well-documented research record in wound repair, with animal studies showing accelerated wound closure and reduced inflammatory markers. In a rat study, topical application of 2% GHK-Cu gel (Iamin) to full-thickness ischemic wounds in 24 Sprague-Dawley rats resulted in 64.5% wound area reduction at day 13⁹, compared to 45.6% for vehicle control and 28.2% for untreated controls. The treated wounds also showed significantly lower concentrations of TNF-alpha and matrix metalloproteinases MMP-2 and MMP-9. However, human clinical data on wound healing remains limited, with most evidence derived from in vitro and animal studies.

Can GHK-Cu help with hair thinning or hair loss?

Animal and lab studies suggest copper peptides may support hair follicle activity, though human clinical data are limited. In fuzzy rats, a copper-binding peptide called PC1031 enlarged hair follicles similarly to topical minoxidil¹⁰. In an ex vivo study, AHK-Cu, a related copper tripeptide, stimulated elongation of human hair follicles¹¹, apparently by promoting dermal papilla cell proliferation and limiting their cell death, while an earlier mouse study¹² reported hair follicle-stimulating properties of peptide copper complexes. However, human randomized controlled trial data for GHK-Cu specifically are lacking.

How does GHK-Cu compare to retinol for skin aging?

GHK-Cu and retinoids address skin aging through distinct mechanisms and carry different tolerability profiles. Retinoids, including retinol and prescription tretinoin, act through nuclear retinoic acid receptors¹³, and irritation is a known trade-off. In a 48-week randomized controlled trial of 99 people with photoaging, 0.1% and 0.025% tretinoin improved photoaging similarly, but erythema and scaling were significantly greater¹⁴ with the 0.1% strength. GHK-Cu is proposed to work through copper delivery and gene regulation. Three 12-week topical GHK-Cu studies⁸, described as placebo-controlled and enrolling 41 to 71 women each, reported improvements in skin laxity, clarity, firmness, and fine lines. Retinoids benefit from a larger evidence base and an FDA-approved prescription form, tretinoin¹⁵. Cross-study comparisons require caution given different formulations, populations, and study designs.

What anti-inflammatory effects does GHK-Cu have?

GHK-Cu modulates NF-κB signaling and is associated with downregulation of pro-inflammatory cytokines in tissue studies. In a mouse lung-injury study, it lowered TNF-alpha and IL-6 by suppressing NF-κB³ signaling, and in rat ischemic wounds it lowered TNF-alpha⁹. A 2012 review of Broad Institute Connectivity Map data from PC3 and MCF7 cells (GHK at 1 μM) reported 268 genes with increased expression¹⁶ and 167 suppressed. In rat wound tissue, GHK also raised superoxide dismutase and catalase levels¹⁷, and across the 13,424 genes in the Connectivity Map data it stimulated 14 antioxidant genes. Among genes GHK changed by at least 50%, 59% were upregulated and 41% suppressed⁴. However, this evidence is primarily at the local/tissue level; elevated CRP and systemic inflammatory markers are not direct targets, and clinical systemic anti-inflammatory effects have not been established.

Also in the library

• Copper tripeptide-1Carrier/copper peptide

More for skin & aging